<DOC>
	<DOC>NCT01020799</DOC>
	<brief_summary>The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.</brief_summary>
	<brief_title>AZD7268 Safety and Tolerability Study</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Provision of signed, written, and dated Informed Consent prior to any study specific procedures Documented primary clinical diagnosis meeting criteria from the DSMIV, Text Revision (APA 2000) for any of the following: 296.2x Major Depressive Disorder, Single Episode, or 296.3x Major Depressive Disorder, Recurrent Patients with a secondary DSMIV Axis I disorder other than GAD or social anxiety disorder (as assessed by MINI), provided the primary diagnosis is MDD. This diagnosis should have been made at least 6 months before enrollment Patients with a diagnosis of DSMIV Axis II disorder which has a major impact on the patient's current psychiatric status Patients whose current episode of depression started less than 4 weeks before enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Depression</keyword>
</DOC>